161 / 510
Cuidados
Continuos
160
induced peripheral neuropathy in patients receiving taxanes and platinums. Cancer Nurs.
2010; 33:173-183.
LoMonaco M, Milone M, Batocchi AP, et al. Cisplatin neuropathy: clinical course and
neurophysiological findings. J Neurol. 1992;239:199-204.
Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy
from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.
Ann Neurol. 1994;35:304-311.
Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity:
acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004; 29:387-392.
Kiernan MC, Burke D, Andersen KV, Bostock H. Multiple measures of axonal excitability: a new
approach in clinical testing. Muscle Nerve. 2000;23:399-409.
Park SB, Lin CS-Y, Krishnan AV, et al. Oxaliplatin-induced neurotoxicity: changes in axonal
excitability precede development of neuropathy. Brain. 2009;132: 2712-2723.
Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era
of pharmacogenomics. Lancet Oncol. 2011;12:1151-1161.
Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of taxol. J Natl Cancer
Inst Monogr. 1993;(15):107-115.
Reeves BN, Dakhil SR, Sloan JA, et al. Further data supporting that paclitaxel-associated
acute pain syndrome is associated with development of peripheral neuropathy: North Central
Cancer Treatment Group trial N08C1. Cancer. 2012;118: 5171-5178.
Beijers AJM, Jongen JLM, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of
neuroprotective strategies.The Neth J of Med 2012; 70 (1):18-25.
Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve
hyperexcitability. J Clin Oncol. 2002;20: 1767-1774.
Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute
neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119:438-
444.
Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D. Impact of oxaliplatin-
induced neuropathy: a patient perspective. Support Care Cancer. 2012;20: 2959-2967.
Argyriou AA, Velasco R, Briani C, et al. Peripheral neurotoxicity of oxaliplatin in combination
with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal
cancer patients. Ann Oncol. 2012;23:3116-3122.
Grothey A, Nikcevich DA, Sloan JA, et al. Intravenous Calcium and Magnesium for Oxaliplatin-
Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7. J Clin Oncol 2011; 29
(4): 421-427.
Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rorth M, Krarup C. Neuronal
involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies.
Brain. 2007;130:1076-1088.
Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC. Cisplatin neuropathy. Clinical,
electrophysiologic, morphologic, and toxicologic studies. Cancer 1984;54:1269–75.
Gregg RW, Molepo JM, Monpetit VJ, et al. Cisplatin neurotoxicity: the relationship between
dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of
toxicity. J Clin Oncol 1992;10:795–803.
Verstappen CCP, Koeppen S, Heimans JJ, et al. Dose-related vincristine-induced peripheral
neuropathy with unexpected off-therapy worsening. Neurology. 2005; 64:1076-1077.
Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ. Long-term effects of
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37